Details

NameSymbolSector
MEDICAMEN BIOTECH LIMITEDMEDICAMEQPharmaceuticals
Open
342
High
363
Low
342
Close
353
Volume
21813
Exchange
nse
Time
14/08

Outlook

Score:  

0

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Medicamen Biotech is  
None
Estimated Stoploss of Medicamen Biotech is ₹  
342
Medicamen Biotech has a  
Bullishℹ
 pattern. 
Formation of  
None
 candle pattern indicates the trend direction of Medicamen Biotech is  
Unpredictableℹ
. 

Trend

Medicamen Biotech is in  
Strong Downtrendℹ
. 
Price of Medicamen Biotech is  
Downℹ
 by  

9.76

%. 
Target
Buy @ 

342

Sell @ 

413

Volume

The trade volumes of Medicamen Biotech have become  
Deficientℹ
The volume trend for Medicamen Biotech is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Medicamen Biotech is  

Down

 by  

19.1

% 

Valuation

The current market price of Medicamen Biotech is  
Overvaluedℹ

Financials

Balance
The balance sheet of Medicamen Biotech is:  

Balanced

Cashflow
Medicamen Biotech has  
Badℹ
 cash flow because there is  

Shortage

 of  

₹ 11cr

. It is  
Downℹ
 by  

120

%. 

(*Mar 2025)

77.78% i.e. ₹ 7cr spent in operatingℹ
11.11% i.e. ₹ 1cr spent in investingℹ
11.11% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Medicamen Biotech has  
Poorℹ
 cash flow because there is  

Shortage

 of  

₹ 5cr

. It is  
Downℹ
 by  

131.25

%. 

(*Mar 2024)

35.29% i.e. ₹ 6cr spent in operatingℹ
29.41% i.e. ₹ 5cr spent in investingℹ
35.29% i.e. ₹ 6cr earned in financingℹ
0% in otherℹ
Income
The income of Medicamen Biotech is  

₹ 43cr

 and  

Profit

 is :  

₹ 1cr

(*Jun 2025)

Medicamen Biotech Profit is up by:  

0

% and Income is Up by:  

26.47

% 

(*Jun 2025)

The income of Medicamen Biotech is  

₹ 34cr

 and  

Profit

 is :  

₹ 1cr

(*Mar 2025)

Medicamen Biotech Profit is down by:  

50

% and Income is Down by:  

24.44

% 

(*Mar 2025)

The income of Medicamen Biotech is  

₹ 45cr

 and  

Profit

 is :  

₹ 2cr

(*Dec 2024)

Medicamen Biotech Profit is up by:  

200

% and Income is Up by:  

0

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.